Kala Pharmaceuticals Inc (NASDAQ:KALA) – Research analysts at Jefferies Financial Group boosted their FY2021 earnings estimates for Kala Pharmaceuticals in a research report issued to clients and investors on Monday, September 14th. Jefferies Financial Group analyst B. Amin now anticipates that the company will earn ($1.52) per share for the year, up from their previous estimate of ($1.56). Jefferies Financial Group currently has a “Hold” rating and a $10.00 target price on the stock. Jefferies Financial Group also issued estimates for Kala Pharmaceuticals’ FY2022 earnings at ($0.73) EPS, FY2023 earnings at $0.05 EPS and FY2024 earnings at $0.58 EPS.

Other equities research analysts have also recently issued research reports about the company. Wedbush reissued a “buy” rating and issued a $39.00 price target on shares of Kala Pharmaceuticals in a research note on Tuesday, August 18th. BidaskClub raised Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 11th. Northland Securities reissued a “buy” rating and issued a $17.00 price target on shares of Kala Pharmaceuticals in a research note on Friday, August 7th. JPMorgan Chase & Co. increased their price target on Kala Pharmaceuticals from $14.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Finally, Oppenheimer started coverage on Kala Pharmaceuticals in a research note on Friday, May 29th. They issued an “outperform” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $18.50.

Shares of KALA stock opened at $8.05 on Wednesday. The stock has a market cap of $451.28 million, a price-to-earnings ratio of -3.55 and a beta of 0.24. The stock has a 50-day moving average of $8.81 and a 200-day moving average of $9.80. The company has a current ratio of 11.63, a quick ratio of 11.29 and a debt-to-equity ratio of 0.56. Kala Pharmaceuticals has a 1-year low of $3.24 and a 1-year high of $14.68.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its earnings results on Thursday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.42). Kala Pharmaceuticals had a negative return on equity of 105.36% and a negative net margin of 1,993.41%.

Large investors have recently made changes to their positions in the business. Invesco Ltd. bought a new position in Kala Pharmaceuticals in the first quarter worth approximately $3,276,000. FMR LLC lifted its holdings in Kala Pharmaceuticals by 64.1% during the second quarter. FMR LLC now owns 4,678,383 shares of the company’s stock worth $49,169,000 after acquiring an additional 1,826,867 shares during the period. BlackRock Inc. lifted its holdings in Kala Pharmaceuticals by 11.1% during the first quarter. BlackRock Inc. now owns 1,581,889 shares of the company’s stock worth $13,906,000 after acquiring an additional 158,283 shares during the period. State Street Corp lifted its holdings in Kala Pharmaceuticals by 18.1% during the first quarter. State Street Corp now owns 428,414 shares of the company’s stock worth $3,766,000 after acquiring an additional 65,576 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Kala Pharmaceuticals by 28,973.9% during the second quarter. Federated Hermes Inc. now owns 188,108 shares of the company’s stock worth $1,977,000 after acquiring an additional 187,461 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: How does a margin account work?

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.